Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The influence of CYP3A5 genotype on tacrolimus pharmacokinetics in patients with SLE.

Rheumatology (Oxford, England) - 6 Apr 2026

Tsuji Hideaki, Onishi Akira, Katada Yoshiki, Ishimura Hiroki, Hira Daiki, Sasai Tsuneo, Shirakashi Mirei, Hiwa Ryosuke, Nakabo Shuichiro, Akizuki Shuji, Nakashima Ran, Yoshifuji Hajime, Tanaka Masao, Terada Tomohiro, Morinobu Akio

Abstract excerpt

OBJECTIVES: Cytochrome P450 3A5 (CYP3A5) gene polymorphisms affect tacrolimus (TAC) pharmacokinetics. However, their impact on the clinical management of SLE remains unclear. This study aims to investigate the influence of CYP3A5 gene polymorphisms on pharmacokinetics of TAC and clinical outcomes in patients with SLE. METHODS: We first analysed the time-averaged TAC trough concentration-to-dose (C/D) ratio...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP3A
Share to CYP3A5 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Immunosuppressive Agents

Share to Lupus Erythematosus, Systemic

Share to Polymorphism, Genetic

Share to Tacrolimus

Source

Identifiers

PMID: 41967124
DOI: 10.1093/rheumatology/keag183

Genes

CYP3A5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The influence of CYP3A5 genotype on tacrolimus pharmacokinetics in patients with SLE.PMID 41967124Read ↗

Dosage optimization of tacrolimus based on the glucocorticoid dose and pharmacogenetics in adult patients with systemic lupus erythematosus.Semantic proximity Read ↗

Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.Semantic proximity Read ↗

Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.Semantic proximity Read ↗

Reduced variability of tacrolimus trough level in once-daily tacrolimus-based Taiwanese kidney transplant recipients with high-expressive genotype of cytochrome P450 3A5.Semantic proximity Read ↗

Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.Semantic proximity Read ↗

Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients.Semantic proximity Read ↗

ABCB1 genetic variant and its associated tacrolimus pharmacokinetics affect renal function in patients with rheumatoid arthritis.Semantic proximity Read ↗

Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration with Wuzhi capsule.Semantic proximity Read ↗

Donor and recipient P450 gene polymorphisms influence individual pharmacological effects of tacrolimus in Chinese liver transplantation patients.Semantic proximity Read ↗

Tacrolimus Therapeutic Drug Monitoring in Stable Kidney Transplantation and Individuation of CYP3A5 Genotype.Semantic proximity Read ↗

Effects of CYP3A5 Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients.Semantic proximity Read ↗

Steroid-tacrolimus drug-drug interaction and the effect of CYP3A genotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.